CHF 56M boost for CUTISS and its next-generation skin graft

CUTISS has closed its Series C round at CHF 56 million, bringing total funding to more than CHF 125 million. The financing will support the Phase 3 trial of its personalized bioengineered skin therapy denovoSkin™ and the scale-up of its automated manufacturing platform.

With the new funds, the Biotech company CUTISS is progressing the clinical development of denovoSkin™, a bilayer skin graft for patients with severe burns and reconstructive needs. The therapy has shown near-scarless regeneration, spares healthy donor skin, and grows with the patient. It holds Orphan Drug Designation in Switzerland, the EU, and the US, and is currently in a confirmatory Phase 3 trial across Switzerland and eight EU member states, with first results expected in 2026.

As part of the Series C round, CUTISS signed an agreement with Rode Kruis Ziekenhuis (RKZ), a leading burn center involved in the trials, which could lead to the company’s first international commercial production facility in the Netherlands. In parallel, CUTISS is preparing the market launch of VitiCell®, a device for treating skin pigmentation disorders, pending new CE marking.

CUTISS has been ranked among the Top100 Swiss Startups and participated in Venture Leaders Life Sciences. "Venture Leaders in Boston has been a fantastic experience and a true door opener to numerous business development opportunities. I had lots of excellent contacts with biotech professionals who can really help to shape our future development," highlighted Co-Founder Daniela Marino.


CUTISS team